Abstract
Alzheimer's disease (AD), a worldwide renowned progressive neurodegenerative disorder, is the most common cause of dementia. There are several studies on the important role of cholesterol metabolism in AD pathogenesis, which indicated that the high concentrations of serum cholesterol increase the risk of AD. Biosynthesis of the plasma cholesterol and other isoprenoids is catalyzed by 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) through the conversion of HMG-CoA to mevalonic acid in mevalonate pathway. Normally, the high level of plasma cholesterol is downregulated by HGMCR inhibition as the result of degradation of LDL, but in abnormal conditions, for example, high blood glucose, the HMGCR over activated resulting in uncontrolled blood cholesterol. Selective HMGCR inhibitor drugs such as statins, which increase the catabolism of plasma LDL and reduce the plasma concentration of cholesterol, have been investigated as a possible treatment for AD. In the present study, we have identified the binding modes of 22 various derivatives of 3-sulfamoylpyrroles 16, prepared via a [3 + 2] cycloaddition of a münchnone with a sulfonamide-substituted alkyne, by using efficient biocomputational tools. Out of 22, 5 ligands, with code number...Continue Reading
References
Jan 1, 1976·Advances in Lipid Research·V W RodwellJ J Mitschelen
Apr 1, 1991·Neuron·D J Selkoe
Jan 1, 1986·Journal of Neuropathology and Experimental Neurology·T I Mandybur
Mar 1, 1995·Toxicology and Applied Pharmacology·B A MastersS K Durham
Aug 13, 1993·Science·E H CorderM A Pericak-Vance
Jun 1, 1997·The Journal of Physiology·N ChiesaE Wanke
Jul 1, 1997·Toxicology and Applied Pharmacology·O P FlintS K Durham
Dec 31, 1997·Journal of Computer-aided Molecular Design·M D EldridgeR P Mee
Dec 20, 1999·Pharmaceutical Research·J KelderJ P Ploemen
Dec 10, 1999·Journal of Medicinal Chemistry· AjayM A Murcko
May 8, 2001·Trends in Pharmacological Sciences·J I VandenbergT J Campbell
Jul 31, 2001·The Journal of Biological Chemistry·R G TironaR B Kim
Mar 30, 2002·Advanced Drug Delivery Reviews·William J Egan, Georgio Lauri
Jul 20, 2002·Journal of Cardiovascular Pharmacology·Helmut SinzingerBernhard A Peskar
Aug 9, 2003·Journal of Medicinal Chemistry·Ailan Cheng, Kenneth M Merz
May 19, 2004·Archives of Neurology·Christiane ReitzRichard Mayeux
Feb 19, 2005·Drug Discovery Today·Alex M Aronov
Aug 4, 2006·Journal of Medicinal Chemistry·Paul D LyneJamal C Saeh
Oct 13, 2006·Journal of Medicinal Chemistry·Richard A FriesnerDaniel T Mainz
Dec 25, 2007·Bioorganic & Medicinal Chemistry Letters·William K C ParkCatherine Sekerke
Sep 9, 2008·Biochemical Pharmacology·Preetha AnandBharat B Aggarwal
Oct 29, 2009·Human Mutation·Paula L HedleyMichael Christiansen
Jan 6, 2010·Journal of Neurochemistry·Ian J MartinsRalph N Martins
Oct 20, 2010·Neuron·Lars BertramRudolph E Tanzi
Mar 31, 2011·Nature Reviews. Neuroscience·Gilbert Di Paolo, Tae-Wan Kim
Apr 8, 2011·Expert Review of Neurotherapeutics·Angel Cedazo-MínguezLaura Mateos
Sep 18, 2012·Molecular Neurobiology·M MaulikS Kar
Apr 17, 2013·Clinical Pharmacology and Therapeutics·K L R BrouwerUNKNOWN International Transporter Consortium
May 23, 2013·The Journal of Biological Chemistry·Laura J Sharpe, Andrew J Brown
Nov 5, 2013·Bioorganic & Medicinal Chemistry·I-Jen Chen, Nicolas Foloppe
Jun 4, 2016·PloS One·Sajad ShahbaziShikha Singh